NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS

Size: px
Start display at page:

Download "NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS"

Transcription

1 NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS

2 Purpose of the Study For patients who have received curative-intent prostate cancer treatment Determine whether more frequent PSA testing leads to better survival or more harm for the patient In order to answer this question, it is important to know every PSA test the patient had To know exactly how frequently a patient is having PSA tests To know if the patient has had a recurrence

3 Thank you for Asking Questions Many questions relate to is this patient eligible? What if I can only get some records for a patient, but not all the records? What if the PCP s office responds but the urologist s office will not respond? The key question is: do you feel you are able to record all the PSAs a patient has had after treatment?

4 Eligibility Criteria 1) Evidence that medical records are available for the patient for 5 years or until distant recurrence or deathwhichever is first 2) For patients who received primary radical prostatectomy: the patient s urologist and primary care physician can be identified For patients who received primary radiotherapy: the patient s radiation oncologist and urologist and primary care physician can be identified 3) The patients has at least 1 PSA test result within 2 years after end of primary treatment and registrar is confident in capturing PSA information for 2 years after primary treatment completion

5 PSA PSA intervals can range from monthly or to once a year. There is a wide variation. Registrars should follow the FORDS manual Example: PSA of 1.2, the registrar can enter 012 or 12. Numerically, these are identical numbers and will not affect the study or data analysis. When a patient has a result of <0.03 or <0.01 or <0.2 (less than some number), we would prefer that you enter the result "0" for this special study. In this sole instance we differ from the FORDS manual, and the example was given in the instructions to specifically show this.

6 Radiation Dose Reminder: Units for Radiation Dose is Gy not cgy 100 cgy = 1 Gy (just like 100 cm = 1 m) If you have already submitted patients in cgy, please send an to specialstudy@facs.org with your FIN and the Special Study IDs.

7 Scan Scans that are clearly not related to prostate cancer or prostate cancer recurrence anywhere in the body do not need to be entered. This is different from what is stated in the instructions. We have made modifications based on feedback from registrars.

8 Testosterone Page 45 typo for units for Total Testosterone values (ng/ml should be ng/dl) For some physicians/hospitals, testosterone testing is routine. For others, it's not. There is variation in clinical practice.

9 Results of Scan There is no old finding option Example: patient had a bone scan in 2007 which found a spine T7 metastasis, and another bone scan in 2008 which found the same metastasis Please choose new finding (options 3 or 4) as the answer, even though this isn t exactly correct

10 Web form Some registrars were having issues with the display of the Additional Clinical Information Tab This issue should be resolved now. We do not have the capabilities to allow for printing or sorting patient lists. We suggest taking screenshots.

11 Study Communication Special Study Website: CAnswer Forum and Standards Resource Library: Please send all study-related questions to Study related questions sent to personal FACS accounts will be forwarded to the Special Study address and a ticket will be created. EITHER send an through the Contact form of the website OR the specialstudy@facs.org address. Please do not send both as all s go to the same account. Include FINs in all communication

12 Issues s for the special study are being sent from the address through an outside server If you have not been receiving these s, send the following information to your IT department and ask them to put us on the whitelist: IP address: ,

13 NCRA Webinar Information NCRA Webinar #1 worth 1.0CE 4/11/17 NCRA Webinar #2 worth 1.0CE 4/18/17 NCRA Webinar #3 worth 1.0CE 4/25/17 NCRA Webinar #4 worth 1.0CE 5/02/17

14 Questions Questions from previous webinar and the Canswer Forum will be included on all webinars. Frequently Asked Questions (FAQ) document will be posted on the website, Canswer Forum, and the web form

15 Review of FAQs from Previous Webinars

16 Gleason Score vs. Pattern Q:When you are asking for the primary biopsy Gleason score and the secondary biopsy Gleason score are you really referring to the primary and secondary pattern? My patient had primary biopsy Gleason score already populated with a 4. Secondary biopsy Gleason score populated with a 3. The score, to me, is the combination of the primary/secondary pattern. A: Both score and pattern are used and are meant to describe the same thing. In this case, Primary Biopsy Gleason Score is 4 and Secondary Biopsy Gleason Score is 3.

17 Recurrence 1. What PSA level should be used to classify a patient as having recurrence? We are not asking registrars to interpret PSA results Please record recurrence if clinical notes indicate recurrence, and/or if patient receives treatment for recurrence 2. Does the patient have recurrence if he was never disease free after treatment? Yes. Please record the date of first PSA test after primary treatment as date of recurrence.

18 Recurrence Q: Patient with a regional recurrence with treatment which progressed to distant metastasis? Do you want both recorded and if so which one do you want the treatment for? A: For recurrence as a whole (biochemical, local, regional, distant), we ask that you capture the first instance of each type of treatment received: hormone therapy, RT, surgery, chemotherapy etc., if the patient received these types of treatments.

19 What should I do if a physician s office does not respond to record requests? If the record request form was faxed, call the office directly to request the records Make sure to send the letter template for patient information from the CoC so the office is aware this data is required for CoC accreditation

20 What if the urologist and PCP are retired? Please see if possible to collect records from their offices. Often, physicians may have retired but records are still available All NPIs are required for each provider If the NPI on the Surveillance tab is unknown: if there is no provider if they have the provider, but the NPI is completely unknown if it is unknown whether they have this provider.

21 NCDB Data Q: Comparing what information the NCDB tab has for a patient to what the medical record contains, there is more information available in the medical record than was initially abstracted. (i.e. Gleason on Prostatectomy and Date of Last Contact). A: Please select No and fill in the updated information. We are looking for the most current data.

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA /9/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA /9/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA 2017-044 5/9/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA 2017-063 6/13/17 Eileen Tonner, MS Study Progress as of 6/13 Number of patients submitted as eligible: 2449 Number

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Project Overview Ronald C. Chen, MD MPH Introductions Principal Investigator: Ronald C. Chen, MD MPH ACS Staff: Eileen Tonner,

More information

Prostate Cancer Dashboard

Prostate Cancer Dashboard Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment

More information

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template Purpose The aim of this ASTRO-sponsored Survivorship Care Plan (SCP) template is to formulate a standardized treatment

More information

FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute

FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute Charlotte, NC National Accreditation Program for Breast

More information

General Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators

General Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS

More information

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR Outcomes Watching It Grow GATRA Annual Conference 2016 Lisa Connor, CTR The abstract begins after case finding The abstract is in progress The abstract is complete The abstract is revisited and nurtured

More information

Commission on Cancer Updates

Commission on Cancer Updates Commission on Cancer Updates OBJECTIVES PROVIDE CANCER REGISTRARS WITH INFORMATION ABOUT CURRENT COC 2018 CHANGES DISCUSS CHANGES RELATED TO CANCER REGISTRY DATA COLLECTION DISCUSS CHANGES RELATED TO CANCER

More information

Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy. Risk Acceptability

Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy. Risk Acceptability Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy Risk Acceptability Versailles, France December 2-4, 2009 Fred A. Mettler Jr. M.,D., M.P.H. New Mexico Federal Regional Medical

More information

PROSTATE CANCER. Mr. Jawad Islam. Consultant Urologist. MBBS, MSc, FRCS(Ed), FEBU, FRCS(Urology) People Centred Positive Compassion Excellence

PROSTATE CANCER. Mr. Jawad Islam. Consultant Urologist. MBBS, MSc, FRCS(Ed), FEBU, FRCS(Urology) People Centred Positive Compassion Excellence PROSTATE CANCER Mr. Jawad Islam MBBS, MSc, FRCS(Ed), FEBU, FRCS(Urology) Consultant Urologist Where is prostate located and what is its function? What is prostate cancer? How common is prostate cancer?

More information

17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom

17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom My Biases Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom I am a member of the specialist group of the Prostate

More information

4/25/ and Beyond: The Survey Process. The Survey Process Survey Process Task Force

4/25/ and Beyond: The Survey Process. The Survey Process Survey Process Task Force 2012 and Beyond: The Survey Process Thomas J. Tachovsky, MD, FACS Chair, Field Staff Sub-Committee, Commission on Cancer St. Luke s Health Care, Bethlehem, PA Lisa Landvogt, CTR Administrator, Commission

More information

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

mehealth for ADHD Parent Manual

mehealth for ADHD Parent Manual mehealth for ADHD adhd.mehealthom.com mehealth for ADHD Parent Manual al Version 1.0 Revised 11/05/2008 mehealth for ADHD is a team-oriented approach where parents and teachers assist healthcare providers

More information

PCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given

PCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given Basic Knowledge: Test for Prostate Cancer Jerry Cross 15 item quiz, no grades given Basic Knowledge: Test for Prostate Cancer From http://prostatesnatchers.blogspot.com/ January 27, 2015 BY MARK SCHOLZ,

More information

Prostate Cancer Patients Charter. The care that you deserve

Prostate Cancer Patients Charter. The care that you deserve Prostate Cancer Patients Charter The care that you deserve Prostate Cancer Patients Charter The Irish Cancer Society is committed to achieving world class cancer services in Ireland. This Charter will

More information

The European Board of Urology

The European Board of Urology Page 1 of 15 The European Board of Urology Sub-specialty certification application: Prostate cancer, A - General information A1 - APPLICATION IDENTIFICATION 1a. Application code blank 1b. EBU internal

More information

Evaluation of Cancer Outcomes Barwon South West Registry

Evaluation of Cancer Outcomes Barwon South West Registry Evaluation of Cancer Outcomes Barwon South West Registry Data Request Form Applicant details Applicant name: Position: Email: Project start date: Date: Telephone: Project completion date: Project details

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER 10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal

More information

Prostate Cancer Local or distant recurrence?

Prostate Cancer Local or distant recurrence? Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative

More information

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.

More information

C o n t e n t s. 2 Introduction. 3 Personal information. 4 Your medical history. 5 PSA results. 7 Healthcare appointments

C o n t e n t s. 2 Introduction. 3 Personal information. 4 Your medical history. 5 PSA results. 7 Healthcare appointments C o n t e n t s 2 Introduction 3 Personal information 4 Your medical history 5 PSA results 7 Healthcare appointments 9 Diagnostic investigations and test results This booklet has been produced jointly

More information

NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions

NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS

More information

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

Illawarra Cancer Care Centre

Illawarra Cancer Care Centre The Audience Who? No apologies! Radiation Oncologists State of Mind Our business Our business is medical Our records are medical records Our information system is electronic medical record Primacy of our

More information

Attachment #2 Overview of Follow-up

Attachment #2 Overview of Follow-up Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

Confessions of a Data Quality Manager

Confessions of a Data Quality Manager Confessions of a Data Quality Manager FCDS Annual Conference Boca Raton, Florida 7/28/2016 Steven Peace, CTR Outline 20 Data Quality Issues in 45 Minutes Reference Dates & Accession Numbers FCDS Reference

More information

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Prostate Cancer Case Study 1. Medical Student Case-Based Learning Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You

More information

Attachment #2 Overview of Follow-up

Attachment #2 Overview of Follow-up Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer

More information

MCR MINI UPDATE DECEMBER 2017

MCR MINI UPDATE DECEMBER 2017 Fellow Registrars, MCR staff are very busy in November double checking our data before sending it to the national level, but we still have some important news, tips and resources to share with you. DUE

More information

Challenging Cases. With Q&A Panel

Challenging Cases. With Q&A Panel Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy

More information

Prostate Cancer Case Study 2. Medical Student Case-Based Learning

Prostate Cancer Case Study 2. Medical Student Case-Based Learning Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy

More information

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason

More information

Personalized Therapy for Prostate Cancer due to Genetic Testings

Personalized Therapy for Prostate Cancer due to Genetic Testings Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center

More information

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

1 : Patient Details. 2 : Medical Aid Details. 3 : Practitioner Detail (Practice) 4 : Patient History

1 : Patient Details. 2 : Medical Aid Details. 3 : Practitioner Detail (Practice) 4 : Patient History 1 : Patient Details Surname: Firstname: Initials: ID Number: First Diagnosed: Gender: Telephone: CellPhone: Dependant Code: Birth: Postal Address Fax: Email: 2 : Medical Aid Details Principal Member: Membership

More information

Please refer to the specific section of the ecqm to identify the QDM data elements and associated value sets for use in reporting this ecqm.

Please refer to the specific section of the ecqm to identify the QDM data elements and associated value sets for use in reporting this ecqm. Page 1 of 5 Page 2 of 5 2014 ecqm Flows Measure Identifier: CMS129v4 NQF 0389: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients Please refer to the specific

More information

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work. Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist Identifying Initial Populations and Sampling for OCM and EBRT Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist January 22, 2015 Learning Objectives Help participants to understand

More information

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) - Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30

More information

PSA is rising: What to do? After curative intended radiotherapy: More local options?

PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung

More information

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement

More information

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement

More information

National Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms

National Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms Form (NOPR) F-18 Fluoride PET Case Report Forms Version Date Patient Information Sheet 06/17/10 (Spanish translation available at: http://www.cancerpetregistry.org/pdf/patient_info_spanish.pdf) Interpreting

More information

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3

More information

Mr PHIP No. 4 Life after treatment for localised prostate cancer

Mr PHIP No. 4 Life after treatment for localised prostate cancer Mr PHIP No. 4 Life after treatment for localised Mr Phip Mr Phip No. 4 / Key points PSA tests are used to monitor cancer control after treatment for. Your PSA drops more quickly after surgery than radiotherapy.

More information

Delivering stratified follow-up in primary care for Prostate Cancer Patients - The NCL Approach. Dr Elizabeth Babatunde Macmillan GP

Delivering stratified follow-up in primary care for Prostate Cancer Patients - The NCL Approach. Dr Elizabeth Babatunde Macmillan GP Delivering stratified follow-up in primary care for Prostate Cancer Patients - The NCL Approach Dr Elizabeth Babatunde Macmillan GP Background 2 Objectives Enhance patient experience and outcomes by providing

More information

Deciding on treatment: a step on your journey.

Deciding on treatment: a step on your journey. Deciding on treatment: a step on your journey. One step at a time. After being told that you have prostate cancer, the next step on your journey may be to participate in the decision on which type of treatment

More information

ProScript User Guide. Pharmacy Access Medicines Manager

ProScript User Guide. Pharmacy Access Medicines Manager User Guide Pharmacy Access Medicines Manager Version 3.0.0 Release Date 01/03/2014 Last Reviewed 11/04/2014 Author Rx Systems Service Desk (T): 01923 474 600 Service Desk (E): servicedesk@rxsystems.co.uk

More information

Creating EVENTS in TPN s Partner Portal Step 1: Scroll down to the footer of the home page and click on PARTNER LOGIN:

Creating EVENTS in TPN s Partner Portal Step 1: Scroll down to the footer of the home page and click on PARTNER LOGIN: Creating EVENTS in TPN s Partner Portal Step 1: Scroll down to the footer of the home page and click on PARTNER LOGIN: Step 1A: You can also access the login portal by going directly to the following link:

More information

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last

More information

for healthcare professionals

for healthcare professionals Fertility toolkit for healthcare professionals We ve developed this toolkit for setting up a fertility referral pathway for young women with breast cancer at the point of diagnosis. We want to help improve

More information

Your Guide to Prostate Cancer

Your Guide to Prostate Cancer Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,

More information

A REPORT ON PRACTICE PATTERN TRENDS IN PROSTATE CANCER

A REPORT ON PRACTICE PATTERN TRENDS IN PROSTATE CANCER A REPORT ON PRACTICE PATTERN TRENDS IN PROSTATE CANCER Date presented to Cancer Committee: September 12, 201 By: Ian Thompson, MD Data by: Shelly Smits, RHIT, CCS, CTR INTRODUCTION: There have been abundant

More information

Date Modified: March 31, Clinical Quality Measures for PQRS

Date Modified: March 31, Clinical Quality Measures for PQRS Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process

More information

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER BLADDER PROSTATE PENIS TESTICLES THE PROSTATE IS A SMALL, WALNUT-SIZED GLAND THAT IS PART OF THE MALE REPRODUCTIVE SYSTEM. IT RESTS BELOW THE BLADDER, IN FRONT OF THE RECTUM AND SURROUNDS PART OF THE URETHRA.

More information

The Prostate Perspective. James Lind Alliance Project Emma Halls & Sandy Tyndale-Biscoe

The Prostate Perspective. James Lind Alliance Project Emma Halls & Sandy Tyndale-Biscoe The Prostate Perspective James Lind Alliance Project Emma Halls & Sandy Tyndale-Biscoe 1 Background Pressure within the Charter for Action that it should include priorities for prostate cancer research

More information

Making the Most of Your Cancer Registry

Making the Most of Your Cancer Registry www.champsods.com Making the Most of Your Cancer Registry Presenter: Toni Hare, Vice President CHAMPS Oncology Data Services Picture of girl here December 11, 2009 Learning Objectives Upon completion of

More information

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools

More information

NAACCR Grade 2018 Q & A

NAACCR Grade 2018 Q & A NAACCR Grade 2018 Q & A GRADE RULES Q: Can you assign a pathologic grade if bx of highest T AND bx of highest N, where case meets criteria for pathologic staging? A:The grade rules indicate for a pathological

More information

Should I get screened for prostate cancer? What you should know about the PSA test

Should I get screened for prostate cancer? What you should know about the PSA test Should I get screened for prostate cancer? What you should know about the PSA test Should I get screened for prostate cancer? What you should know about the PSA test > What is PSA? Prostate-specific antigen

More information

Providing Treatment Information for Prostate Cancer Patients

Providing Treatment Information for Prostate Cancer Patients Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact

More information

Helen Forristal MSc (ANP) ; BSc (Hons) Professional Nursing Hormonal Treatment for Prostate Cancer ANP Candidate - Urology 2011

Helen Forristal MSc (ANP) ; BSc (Hons) Professional Nursing Hormonal Treatment for Prostate Cancer ANP Candidate - Urology 2011 Helen Forristal MSc (ANP) ; BSc (Hons) Professional Nursing Hormonal Treatment for Prostate Cancer ANP Candidate - Urology 2011 What is my Objective? If you see a patient, you may only see someone with

More information

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES OVERVIEW Diagnosis Laboratory Tests PSA Free and Total PSA PCA-3 4K Score The

More information

PET imaging of cancer metabolism is commonly performed with F18

PET imaging of cancer metabolism is commonly performed with F18 PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate

More information

The Center for Cancer Prevention and Treatment Public Reporting of Outcomes

The Center for Cancer Prevention and Treatment Public Reporting of Outcomes The Center for Cancer Prevention and Treatment 2017 Public Reporting of Outcomes Cancer Screening Program - CoC Standard 4.2 Oral Cancer Screening Event Identified Community Need According to the 2014

More information

Prostate Overview Quiz

Prostate Overview Quiz Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the

More information

Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate

Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Article ID: WMC003222 ISSN 2046-1690 Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Corresponding Author: Mr.

More information

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support

More information

Medication Prior Authorization Form

Medication Prior Authorization Form Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide

More information

The Prostate Cancer Surgery Tick List. Use these questions as starters for your first meeting with your prostate cancer surgeon.

The Prostate Cancer Surgery Tick List. Use these questions as starters for your first meeting with your prostate cancer surgeon. The Prostate Cancer Surgery Tick List Use these questions as starters for your first meeting with your prostate cancer surgeon. Print these out and had to your doctor at the start of your meeting. Tick

More information

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate

More information

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in

More information

Troubleshooting Audio

Troubleshooting Audio Welcome! Audio for this event is available via ReadyTalk Internet Streaming. No telephone line is required. Computer speakers or headphones are necessary to listen to streaming audio. Limited dial-in lines

More information

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use OneTouch Reveal Web Application User Manual for Healthcare Professionals Instructions for Use Contents 2 Contents Chapter 1: Introduction...4 Product Overview...4 Intended Use...4 System Requirements...

More information

ASST Papa Giovanni XXIII

ASST Papa Giovanni XXIII ASST Papa Giovanni XXIII General info Unit Director: Marco Roscigno, Interdisciplinary and Multiprofessional Team Core Team Urologists, Radiation Oncologists, Medical Oncologists, Pathologists, Data Managers

More information

Date Modified: May 29, Clinical Quality Measures for PQRS

Date Modified: May 29, Clinical Quality Measures for PQRS Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

New research in prostate brachytherapy

New research in prostate brachytherapy New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic

More information

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in

More information

GREATER BALTIMORE MEDICAL CENTER SANDRA & MALCOLM BERMAN CANCER INSTITUTE

GREATER BALTIMORE MEDICAL CENTER SANDRA & MALCOLM BERMAN CANCER INSTITUTE GREATER BALTIMORE MEDICAL CENTER SANDRA & MALCOLM BERMAN CANCER INSTITUTE CANCER REGISTRY REPORT The Cancer Data Management System/Cancer Registry collects data on all types of cancer diagnosed or treated

More information

Please submit all questions concerning webinar content through the Q&A panel. Reminder:

Please submit all questions concerning webinar content through the Q&A panel. Reminder: NAACCR 2015-2016 Clinical Outcomes and Webinar Quality Series Improvement: Oncology Dashboard Drivers NAACCR Webinar Series 2016 2017 Lisa D. Landvogt, BA, CTR LLandvo1@hfhs.org Jocelyn Hoopes, MLIS, CTR,

More information

PROSTATE CANCER CONTENT CREATED BY. Learn more at

PROSTATE CANCER CONTENT CREATED BY. Learn more at PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL

More information

2011 PROSTATE BRACHYTHERAPY STUDY

2011 PROSTATE BRACHYTHERAPY STUDY 20 PROSTATE BRACHYTHERAPY STUDY CRITERIA Patients receiving prostate brachytherapy at Cox from 2002-200. In this study, we will look at patients with the following prognostic features: PSA

More information

The Selenium and Vitamin E Prevention Trial

The Selenium and Vitamin E Prevention Trial The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the

More information

Blue Distinction Centers for Fertility Care 2018 Provider Survey

Blue Distinction Centers for Fertility Care 2018 Provider Survey Blue Distinction Centers for Fertility Care 2018 Provider Survey Printed version of this document is for reference purposes only. A completed Provider Survey must be submitted via the online web application

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

Prostate Cancer UK s Best Practice Pathway

Prostate Cancer UK s Best Practice Pathway Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason

More information

If you have aggressive cancer, you would want treatment in time for a cure.

If you have aggressive cancer, you would want treatment in time for a cure. Prostate cancer: PSA screening, biopsy, new technologies The treatment/cure should never be worse than the disease. If you have aggressive cancer, you would want treatment in time for a cure. What is PSA?

More information

Prostate cancer. A guide for men who ve just been diagnosed

Prostate cancer. A guide for men who ve just been diagnosed Prostate cancer A guide for men who ve just been diagnosed 2 Prostate cancer A guide for men who ve just been diagnosed About this booklet This booklet is for men who ve recently been diagnosed with prostate

More information

Notes: Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer

Notes: Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer Notes: Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer Comments, Feedback? Contact Patient and Professional Education 519 685 8742 Email: lrcpeducation@lhsc.on.ca Reviewed

More information